FJ
Therapeutic Areas
Keros Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| KER-050 (Eltritercept) | Myelodysplastic Syndromes (MDS) | Phase 2 |
| KER-012 | Pulmonary Arterial Hypertension (PAH) | Phase 2 |
Leadership Team at Keros Therapeutics
JS
Jasbir S. Seehra, Ph.D.
President, Chief Executive Officer, Director
KR
Keith Regnante, CPA
Chief Financial Officer
SC
Simon Cooper, M.B. B.S.
Chief Medical Officer
CT
Claude T. D. Harbour, Ph.D.
Senior Vice President, Technical Operations
CR
Christopher R. Bowman, M.D.
Vice President, Clinical Development
JC
Julian C. Baker
Director